François Hellot

francois-hellot

François Hellot

François Hellot focuses his practice on M&A, private equity and capital markets transactions for public and private companies, with experience in both French and international matters. He has extensive experience representing investment funds, family offices, issuers and managers in private equity transactions, including leveraged buyouts, venture capital, growth capital and capital markets.

Mr. Hellot has experience working in a wide range of industries, including  the healthcare, biotech, telecoms, energy services (oil and gas), and digital sectors.

Mr. Hellot is noted by clients for his “experience, insight and commitment” in The Legal 500 EMEA 2017, where he is recommended in France: private equity: venture and growth capital. He is also recognized for France: Capital Markets ‒ Equity; M&A; and Private Equity by IFLR1000, 2018.

Prior to joining Dechert, Mr. Hellot was a partner in the Paris office of another international law firm.

Experience
  • Counsel of Certares with its investment in Marietton group.
  • Counsel of Continental with the share capital increase of Easymile.
  • Counsel of Bryan Garnier & Co Ltd and RBC Europe Limited with the public offering of Biom’Up.
  • Counsel of Orange in its acquisition of Enovacom, a leading healthcare software company.
  • Financial intermediaries in the context of a French specialist in surgical hemostasis' IPO on compartment C of the Euronext regulated market in Paris.
  • An American financial company in connection with its acquisition of a global provider of integrated travel technology. 
  • A French industrial company specializing in chemicals for the construction materials, as well as its managers and shareholders in the context of a secondary LBO and build-ups.
  • An online retailer for organic, eco-friendly and wellness products and its main shareholders in the context of its acquisition by one of the world’s leading food retail operators.
  • One of the world’s leading telecommunications operators with its acquisitions of two mobile operators in Sierra Leone and in Burkina Faso.
  • A biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes and listed on Euronext Paris in the context of its IPO and of several private placements for a total amount of 95M€.
  • One of the world’s leading telecommunications operators in the sale of its stake in Kenya’s incumbent mobile and fixed-line operator.
  • An innovative biotechnology company on the success of its IPO in compartment C of the Euronext regulated market in Paris by means of a capital increase and a private placement for a total amount of 40M€.
  • A biotech specializing in the treatment of inner ear diseases in connection with a capital increase via €8 million private placement with a US-based family office specialized in life sciences.
  • A biopharmaceuticals company listed on the Copenhagen Stock Exchange on its cross-border merger with a company specializing in the development of orphan drugs in oncology.
  • A non-profit organization on the creation of its new e-shop label.
Education
  • Université Paris 1 Panthéon-Sorbonne, DEA, 1994
  • Institut d’Études Politiques de Paris (Sciences Po), 1994
  • Institut d’Études Politiques de Paris (Sciences Po), Economics and Finance, 1994
Admissions
  • Paris
Languages
  • French
  • English